Thomas M. Harrington
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Thomas M. Harrington has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Eric D. Newman
Geisinger Medical Center, Danville, Pennsylvania
2 shared publicationsBrian DO DelVecchio
From the Geisinger Medical Center, Danville, Pennsylvania, Danville, PA
1 shared publicationDennis Torretti
Geisinger Clinic Danville, PA
1 shared publicationDuane E. Davis
Geisinger Clinic Danville, PA
1 shared publicationJames L. Perruquet
Geisinger Clinic Danville, PA
1 shared publicationJana L. Antohe
Geisinger Medical Center, Danville, Pennsylvania, Danville, PA 17822, USA
1 shared publication
Latest Publications
- Open Access
- 29 October 2009
- Published by Wiley in Arthritis Care & Research
- Vol. 61 (11) , 1505-1510
Improved influenza and pneumococcal vaccination in rheumatology patients taking immunosuppressants using an electronic health record best practice alert
Objective: To examine whether an electronic health record (EHR) best practice alert (BPA), a clinical reminder to help guideline adherence, improved vaccination rates in rheumatology patients receiving immunosuppressants. Guidelines recommend yearly influenza and pneumococcal vaccination with revaccination for patients age >65 years who are taking immunosuppressive medications.Methods: A vaccination BPA was developed based on immunosuppressant treatment, age, and prior vaccinations. At site 1, a hospital‐based academic practice, physicians ordered vaccinations. At site 2, a community‐based practice, physicians signed orders placed by nurses. Demographics, vaccination rates, and documentation (vaccination or no administration) were obtained. Chi‐square and Fisher's exact test analysis compared vaccination and documentation rates for October 1 through December 31, 2006 (preBPA), and October 1 through December 31, 2007 (postBPA). Breslow‐Day statistics tested the odds ratio of improvement across the years between the sites.Results: PostBPA influenza vaccination rates significantly increased (47% to 65%;P< 0.001), with significant improvement at both sites. PostBPA pneumococcal vaccination rates likewise significantly increased (19% to 41%;P< 0.001). PostBPA documentation rates for influenza and pneumococcal vaccinations also increased significantly. Site 2 (nurse‐driven) had significantly higher preBPA vaccination rates for influenza (69% versus 43%;P< 0.001) than pneumococcal (47% versus 15%;P< 0.001).Conclusion: The use of a BPA significantly increased influenza and pneumococcal vaccination and documentation rates in rheumatology patients taking immunosuppressants. A nurse‐driven process offered higher efficacy. An EHR programmed to alert providers is an effective tool for improving quality of care for patients receiving immunosuppressants.
- 29 October 2009
- Published by Wiley in Arthritis Care & Research
- Vol. 61 (11) , 1505-1510
Open AccessImproved influenza and pneumococcal vaccination in rheumatology patients taking immunosuppressants using an electronic health record best practice alert
Objective: To examine whether an electronic health record (EHR) best practice alert (BPA), a clinical reminder to help guideline adherence, improved vaccination rates in rheumatology patients receiving immunosuppressants. Guidelines recommend yearly influenza and pneumococcal vaccination with revaccination for patients age >65 years who are taking immunosuppressive medications.Methods: A vaccination BPA was developed based on immunosuppressant treatment, age, and prior vaccinations. At site 1, a hospital‐based academic practice, physicians ordered vaccinations. At site 2, a community‐based practice, physicians signed orders placed by nurses. Demographics, vaccination rates, and documentation (vaccination or no administration) were obtained. Chi‐square and Fisher's exact test analysis compared vaccination and documentation rates for October 1 through December 31, 2006 (preBPA), and October 1 through December 31, 2007 (postBPA). Breslow‐Day statistics tested the odds ratio of improvement across the years between the sites.Results: PostBPA influenza vaccination rates significantly increased (47% to 65%;P< 0.001), with significant improvement at both sites. PostBPA pneumococcal vaccination rates likewise significantly increased (19% to 41%;P< 0.001). PostBPA documentation rates for influenza and pneumococcal vaccinations also increased significantly. Site 2 (nurse‐driven) had significantly higher preBPA vaccination rates for influenza (69% versus 43%;P< 0.001) than pneumococcal (47% versus 15%;P< 0.001).Conclusion: The use of a BPA significantly increased influenza and pneumococcal vaccination and documentation rates in rheumatology patients taking immunosuppressants. A nurse‐driven process offered higher efficacy. An EHR programmed to alert providers is an effective tool for improving quality of care for patients receiving immunosuppressants.
- 1 January 2006
- Published by Taylor & Francis in Journal of Orthopaedic Medicine
- Vol. 28 (2) , 69-71
Knee Effusions as a Complication of Hyaluronic Injections: A Case Series
HylanG-F20 (Synvisc) viscosupplementation is a relatively new medical intervention used in the treatment of osteoarthritis of the knees. There has been some controversy as to the frequency of local reaction secondary to the instillation of this material. A retrospective review of all patients who underwent hylan injection at Geisinger Medical Center revealed 16 out of 332 patients as having an acute local reaction thus indicating a 4.8% incidence of hylan flare. Acute localized pain, swelling and effusion characterized this reaction which generally occurred within 24 hours of hylanG-F20 injection. Arthrocentesis revealed a sterile effusion without microcrystals in all 16 of the knee flares and with a low to moderate leukocyte count of 87-9550 in 12 out of the 16 patients. The acute local reaction resolved with only conservative care (nonsteroidal anti-inflammatory drugs (NSAIDs) and ice or arthrocentesis followed by intra-articular steroids). Our case series supports prior studies that have reported the incidence of acute local reactions at approximately 5%. The cause of this reaction remains unclear.
- 1 January 2006
- Published by Taylor & Francis in Journal of Orthopaedic Medicine
- Vol. 28 (2) , 69-71
Knee Effusions as a Complication of Hyaluronic Injections: A Case Series
HylanG-F20 (Synvisc) viscosupplementation is a relatively new medical intervention used in the treatment of osteoarthritis of the knees. There has been some controversy as to the frequency of local reaction secondary to the instillation of this material. A retrospective review of all patients who underwent hylan injection at Geisinger Medical Center revealed 16 out of 332 patients as having an acute local reaction thus indicating a 4.8% incidence of hylan flare. Acute localized pain, swelling and effusion characterized this reaction which generally occurred within 24 hours of hylanG-F20 injection. Arthrocentesis revealed a sterile effusion without microcrystals in all 16 of the knee flares and with a low to moderate leukocyte count of 87-9550 in 12 out of the 16 patients. The acute local reaction resolved with only conservative care (nonsteroidal anti-inflammatory drugs (NSAIDs) and ice or arthrocentesis followed by intra-articular steroids). Our case series supports prior studies that have reported the incidence of acute local reactions at approximately 5%. The cause of this reaction remains unclear.
- 1 February 1995
- Published by Wiley in Arthritis & Rheumatism
- Vol. 38 (2) , 297
Creating a care‐effective cost‐effective strategy for methotrexate liver toxicity monitoring in rheumatoid arthritis: comment on the article by kremer et al
- 1 February 1995
- Published by Wiley in Arthritis & Rheumatism
- Vol. 38 (2) , 297
Creating a care‐effective cost‐effective strategy for methotrexate liver toxicity monitoring in rheumatoid arthritis: comment on the article by kremer et al